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Abstract 
Background:  CareStart™ Malaria Pf/Pv Combo test has shown encouraging results for the diagnosis of P. falciparum 
and P. vivax infections in Ethiopia. Nevertheless, the performance of the test could be affected by different factors like 
gene polymorphisms, excess heat and humidity. Hence, evaluation of the performance of the test in different settings 
in Ethiopia is vital for the routine diagnosis of malaria.  
Objective: To evaluate the diagnostic performance of CareStart
TM
 Malaria Pf/Pv Combo test for the diagnosis of P. 
falciparum and P. vivax infections in the Afar Region, Northeast Ethiopia. 
Methods: Finger prick blood samples were collected from a total of 1092 patients who had malaria symptoms and 
visited three different health facilities in the Afar Region. Giemsa-stained thin and thick blood smears were prepared 
and microscopically examined under 100 × magnifications for Plasmodium species identification and determination of 
parasitaemia. CareStart Malaria Pf/Pv Combo test was also performed as per the manufacturer's instructions. The 
sensitivity and the specificity of the test was determined using microscopy as gold standard.  
Results: The sensitivity and specificity of the test were 98.5% and 98.0% respectively, with a positive predictive value 
(PPV) of 91.7% and a negative predictive value (NPV) of 99.7% for the diagnosis of P. falciparum infection. The 
corresponding sensitivity and specificity for the diagnosis of P. vivax infection were 100% and 99.6% respectively, 
with PPV and NPV of 86.2% and 100%, respectively. 
Conclusion: The results of this study revealed high sensitivity and specificity of CareStart
TM
 Malaria Pf/Pv Combo 
test for the diagnosis of both P. falciparum and P. vivax infections in the study area, though additional study may be 
needed in the most peripheral hottest areas of the region.  [Ethiop. J. Health Dev.  2011;25(3):206-211] 
 
Background  
Malaria affects approximately 300-400 million people 
and causes 1-2 million deaths every year worldwide (1). 
The disease remains endemic in 109 countries, of which 
45 countries are in Africa (2). In Ethiopia, About 75% of 
the total area of the country is estimated to be malarious, 
while more than two thirds of the total population is at 
risk of infection (3). The annual number of malaria cases 
in Ethiopia is as high as 10-15 million (4) and mainly 
caused by infection with P. falciparum and P. vivax. 
 
Accurate and rapid diagnosis
 
of malaria is not only the 
cornerstone for preventing morbidity and mortality, but 
also for avoiding unnecessary use of anti-malarial drugs. 
In many settings in Africa, presumptive treatment of all 
fevers
 
as malaria results in extensive overuse of anti-
malarial drugs and
 
delays the diagnosis of other causes of 
fever (5). Light microscopy is presently the gold standard 
for malaria diagnosis. However, its low sensitivity in the 
case of low level of parasitemia, especially in patients 
infected with P. falciparum (6) necessitates other 
effective and rapid diagnostic tests.  
 
Rapid diagnostic tests (RDTs) for the diagnosis of 
malaria have been developed and recognized by WHO as 
potential solutions to overcome the limitations with 
microscopy (7, 8). Using RDTs have several advantages 
particularly in peripheral health facilities such as health 
posts. They: require no capital investment or electricity, 
are simple to perform, and are easy to interpret. Users 
such as community health workers (at health posts) with 
little or no laboratory experience can be quickly trained 
in their use, result is available within a short time thus 
accelerating case-management and can fill diagnostic 
gaps at health facilities where microscopy is not available 
and the like.  
 
However, RDTs also have some disadvantages: not 
possible to quantify the parasitic load and able to assess 
anti-malaria treatment. This might be because of the false 
positivity  due to the persistence of HRP 2 antigen in 
patients who had been treated for one month in case of P. 
falciparum (9). 
 
Among commercially available RDTs, CareStart™ 
Malaria test has been showing encouraging results for the 
diagnosis of the various species of Plasmodium parasites 
that infect humans in various countries (10, 11). For 
instance, CareStart Pf/Pv Combo test fulfills the 
performance criteria set for the rapid diagnosis of malaria 
(12), by attaining sensitivity greater than 95% for 
samples with parasitemia≥100 parasites/µl of blood. 
RDTs employ lateral-flow immune-chromatographic 
technology. Whereby, the clinical sample migrates as a 
liquid across the surface of a nitrocellulose membrane by 
means of capillary action (13, 14). For a targeted parasite 
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antigen, two sets of antibodies, a capture and detection 
antibodies, are used. The capture antibodies are sprayed 
as a stripe by machine onto the nitrocellulose membrane 
and bound to the membrane in an immobile phase. These 
fixed antibodies serve to extract and bind parasite antigen 
from the migrating liquid sample. The second set of 
antibodies is conjugated to an indicator, typically gold 
particles, in a mobile phase. These antibody-indicator 
complexes bind to the parasite antigen that has been 
captured by the immobile antibody on the membrane, 
producing a visible line if the targeted antigen is present 
in the clinical sample (8, 14).  
 
In Ethiopia, the performance of CareStart
TM
 Malaria 
Pf/Pv Combo test, which is based on the detection of 
HRP-2 antigen for P. falciparum and pLDH antigen for 
P.vivax was evaluated in southern Ethiopia. The study 
showed sensitivity of 99.4%, and specificity of 98% with 
PPV of 94.4% and NPV of 99.8% for the diagnosis of P. 
falciparum infection. The corresponding value of 
sensitivity, specificity, PPV and NPV of the test for the 
diagnosis of P.vivax were 99.4%, 98.2%, 94.5% and 
99.8%, respectively (15). A similar study showed a 
sensitivity of 95.8% and specificity of 100% with PPV of 
100% and NPV of 96% (16) for the diagnosis of P. vivax. 
 
Nevertheless, it is important to evaluate CareStart
TM
 
Malaria Pf/Pv Combo test in different geographical areas 
of Ethiopia since the performance of the test can be 
affected by different factors like ambient conditions, and 
variability within the parasite antigen being detected by 
the RDT (12, 17). Hence, this study was conducted to 
assess the sensitivity, specificity and predictive values of 
the CareStart Malaria Pf/Pv Combo test, in patients 
conformed of malaria using Giemsa stained blood films 
as reference in the Afar Region, north east Ethiopia. The 
hypothesis of the study was that CareStart
TM
 Malaria 
Pf/Pv Combo test would have comparable diagnostic 
performance with light microscopy for the diagnosis of 
both P. falciparum and P. vivax infections with 
sensitivity and specificity greater than 95%. 
 
Methods 
Study Area and Population 
A cross-sectional health facility based study was 
conducted at MelkaWerer Health Centre, Gewane Health 
Centre and Dubti Hospital of the Afar Region from 
December 2009 to January 2010. The Afar Region is 
located in the Great East African Rift Valley in the 
northeastern part of Ethiopia.  The altitude of the region 
ranges from 1500 meters above sea level to 166 meters 
below sea level, while the temperature varies from 25ºC 
during the wet to 48ºC during the dry season. Rainfall is 
erratic and scarce, and the annual precipitation ranges 
from 200 mm to 600 mm. Dubti Hospital is located at 
574 km from Addis Ababa and it has an average 
elevation of 503 meters above level, while its annual 
temperature ranges from 20 ºC to 45 ºC. Melka Werer 
Health Centre is located at 270 km from Addis Ababa 
with an average elevation of 740 meters above sea level 
and its annual temperature ranges from 19 ºC to 34 ºC.  
Gewane Health Centre which is located at 365 km from 
Addis Ababa has an average elevation of 550 meters and 
annual temperature ranging from 33.2 ºC to 42.5 ºC. 
 
The epidemiological pattern of malaria transmission in 
Ethiopia is generally seasonal and highly unstable due to 
variations in topography and rainfall patterns. In the Afar 
Region it is generally unstable, with perennial 
transmission in areas along the Awash River Valley (18).  
 
The study subjects consisted of all febrile patients who 
had clinical symptoms of malaria fever of malaria and 
visited the outpatient department (OPD) of the three 
health facilities. There were no exclusion criteria unless 
the patient or the guardians (in case of children less than 
18 years old) did not volunteer to participate in the study. 
 
Sample Size Determination 
At present, there is no reliable information on the 
performance characteristics of CareStart
TM
 Malaria Pf/Pv 
Combo test in the study area. However, the sample size 
was calculated, based on the sensitivity and specificity of 
the test to be 95% (12), using the sample size calculation 
formula n = (Z/D)
2 
x P(1-P) ,where n = sample size, Z = 
95% confidence interval (1.96),  D = Margin of error 
(5%),  P = Sensitivity/ Specificity (95%). 
 
Based on this assumption, a minimum number of 83 
blood film positive and 83 blood film negative patients 
(166 for P. falciparum and 166 for P. vivax) were 
stipulated to be included in the study for each study area. 
However, to increase the reliability of the test, more 
subjects were recruited to participate in the study. 
 
Data Collection    
Thick and thin blood films were prepared from finger 
prick blood, stained with Giemsa for 10 minutes and 
examined under 1000X magnification. Parasite densities 
(parasites/µl of blood) were calculated by assuming 8000 
WBCs/µl whole blood. Thus, parasites in thick-film 
fields were counted until 200 WBCs were examined, and 
the parasite count multiplied by 40 to give the number of 
parasites per micro liter of blood and the species of 
Plasmodium were identified using thin smear (19).  A 
minimum of one hundred high power fields were 
examined on a thick film before a negative result was 
declared (15). 
 
In this study, we used CareStart 
TM
 Malaria Pf/Pv Combo 
test (Lot No H38 IV and Lot No H28 IV) to screen 
patients. CareStart 
TM
 Malaria Pf/Pv Combo test (Lot No 
H28 IV) was stored at ambient temperatures of Dubti 
Hospital for one year without controlling the system of 
the storage temperature. The CareStart
TM 
Malaria Pf/Pv 
Combo test Lot No H38 IV was stored at local 
temperature in Addis Ababa for about 6 months before 
starting the study.  The CareStart 
TM
 Malaria Pf/Pv 
Combo test was performed according to the instruction of 
the manufacturer (Access Bio, Inc., New Jersey, USA). 
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Malaria Pf/Pv Combo test 
device was given an identification code similar to the 
code used on the slide for each study subject. About 5 µl 
of fresh blood sample was added on the test device 
window using the sample applicator provided with the kit 
and followed by adding 3 drops (60 µl) of reagent buffer. 
The device was left aside for 20 minutes at room 
temperature and the results were recorded as positive, 
negative or invalid. 
 
Quality Control 
Test kits were kept at the local temperature of the region 
without any controlling system of the storage temperature 
during data collection. Quality of package desiccant was 
checked before use. The results of the RDTs and 
microscopy examination were recorded on separate 
sheets with similar identification code for each study 
subject. To minimize observational
 
bias, experienced 
malaria technicians performed the microscopic 
examination of the giemsa stained blood film and the 
CareStart
TM
 pf/pv malaria Combo test independently. 
The results of their observation were recorded for later 
comparison on separate sheets to ensure accuracy. 
Moreover, at the end of the study, 20% of the positive 
and 10% of the negative slides and discordant results 
between CareStart
TM
 Malaria Pf/Pv Combo test and those 
of microscopy were examined by another well 
experienced technician. Data collection, examination and 
recording were supervised by the investigators. 
 
Ethical Considerations  
The study protocol was approved by the Ethical 
Clearance Committee of the Aklilu Lemma Institute of 
Patho-biology, Addis Ababa University. The aim of the 
study was explained to each participant and their verbal 
consent was obtained. Study participants, who were 
found positive for P. falciparum, were treated with an 
Artemisinin combination therapy (ACT), while those 
positive for P. vivax were treated with chloroquine 
according to the treatment protocol of the National 
Guideline. 
 
Data analysis  
The data were entered using EpiData Version 3.1 and 
analyzed using Stata 8 software. Sensitivity, specificity 
and predictive values of the CareStart
TM
 malaria test were 
calculated using microscopy as the gold standard. The 
following equations were used to calculate the 
sensitivity, specificity and predictive values of the assay 
(16). 
Sensitivity = a/n1×100 
Specificity = b/n2×100 
Positive predictive value = a/n3×100 
Negative predictive value = b/n4×100 
 
where n1 = number of true positives identified by 
microscopy; n2 = number of true negatives confirmed 
through microscopy; n3 = number of cases identified as 
positives by RDT test; n4 = number of cases identified as 
negatives by the RDT test; a = number of cases identified 
as positives by microscopy and by the RDT test; b = 
number of cases identified as negatives by microscopy 
and by the RDT test. 
 
Results 
A total of 1092 patients suspected of malaria were 
screened by microscopy and the CarStart
TM
 malaria 
Combo test. Of those, 675 (61.81%), 238 (21.8%) and 
179 (16.4%) were from Melkawerer, Gewane Health 
Centers and Dubti Hospital, respectively. Of the total 
participants, 527 (48.57%) were females and 558 
(51.43%) males with ages ranging from 3 months to 78 
years old (mean ± SD age = 22.3 ± 12.8 years).  The 
gender of 7 individuals was not recorded. One hundred 
and six   subjects (12.5%) had anti-malarial therapy in the 
preceding one month. Table 1 shows the socio-
demographic and baseline characteristics of the study 
subjects. 
 
Table 1: Socio-demographic and baseline 
characteristics of febrile cases suspected for malaria 
Afar Region, Northeastern Ethiopia, December 2009 
to January 2010 
Characteristics  Number (%) 
Gender 
Male  









5 - 10 yrs 






 752  (68.9) 






ND = Not determined 
 
Microscopic blood film examination indicated 201 (18.4 
%), 23 (2.1%) and 2 (0.2%) of the total study subjects as 
positive for P. falciparum, P. vivax and mixed infections, 
respectively. On the other hand, 212 (19.4%), 27 (2.5%) 
and 4 (0.4%) were positive for P. falciparum, P. vivax, 
and mixed infections, respectively, by the CareStart
TM
 
combo test. Out of the 201 subjects who were positive for 
P. falciparum infection by microscopy, 196 (97.5%), 2 
(0.99 %) and 3 (1.5%) were found positive for P. 
falciparum, P. vivax and negative, respectively by the 
Care Starttest
TM
.  All the 23 subjects found positive for P. 
vivax by microscopy were also found positive for P. 
vivax infection by CareStart
TM
 test (Table 2). Again 18 
and 4 subjects, who were found negative by microscopy 
for P. falciparum and P. vivax infections, respectively, 
were found to be positive by the CareStart
TM
. Of those, 7 
cases had history of malaria treatment within one month 
prior to the study. 
 
Eighty patients were screened by CareStart
TM
 (Lot No 
H28IV) which was stored at the ambient temperature of 
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Afar Region parallel with CareStart
TM
 (Lot No H 38IV) 
which was stored at Addis Ababa. Similar results were 
obtained by both tests (Table 3). 
 
Table 4 depicts the sensitivity and specificity of the 
CareStart
TM
 test for the diagnosis of P. falciparum and P. 
vivax infections. The sensitivity and specificity of the test 
were 98.5% and 98.0% respectively, with PPV of 91.7% 
and NPV of 99.7%. The corresponding sensitivity and 
specificity for the diagnosis of P. vivax infection were 
100% and 99.6%, respectively, with PPV and NPV of 




 test for the detection of P. 
falciparum had a sensitivity of 100% for samples with 
parasitemias > 100 parasites/µl and its sensitivity 
declined lower than 62.5% for samples with parasitemia 
< 100. Table 5 depicts the sensitivity of CareStart™ 
Malaria PF/Pv Combo test for the diagnosis of P.  
falciparum infections at different levels of parasitemia.  
Regarding each study site, the sensitivities were 100%, 
100% and 98.4% at Dubti Hospital, Gewane and 
Melkawerer health centres, respectively. The specificities 
were 98.2% at Dubti, 100% at Gewane and 96.6% at 
Melkawerer. 
 
Table 2: Performance of CareStart 
TM
 Malaria Pf/Pv Combo Test for the Diagnosis of P. falciparum  
and P. vivax Infections in the Afar Region, Northeastern Ethiopia, December 2009 to January 2010 
Microscopic Results     No    
samples 
            CareStart Pf/Pv results 
P. falciparum P. vivax Mixed Negative 
 P.falciparum   201      196     2     0    3 
 P.vivax    23         0    23     0    0 
 Mixed    2         0     0     2    0 
 Negative   866        16     2     2   846 





Table 3: Comparison of CareStart 
TM
 Malaria Pf/Pv Combo Test (Lot No H28IV) and CareStart  
TM
 Malaria Pf/Pv Combo Test (Lot No H38IV) for the Diagnosis of P. falciparum and P.vivax Infections  










(Lot No H28IV) 
Microscopy 
 P. falciparum  29 29 29 
 P. vivax 9 9 9 
 Mixed 2 2 2 
 Negative 40 40 40 





Table 4: Sensitivity and Specificity of CareStart 
TM
 Malaria Pf/Pv Combo Test for the Diagnosis of P. falciparum 
and P. vivax Infections in the Afar Region, Northeastern Ethiopia, December 2009 to January 2010 
  Microscopy     
CareStart
TM
  Positive  Negative  Sensitivity %  Specificity % 
 Positive 198  18 98.5 98.0 
 P. falciparum Negative          3  873   
 Positive           23                         4                  100 99.6 
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Table 5:  Over all Sensitivity of CareStart™ Malaria PF/Pv Combo Test for the Detection of P. falciparum at 
Different Levels of Parasitemia in the Afar Region, Northeastern Ethiopia, December 2009 to January 2010 
 
Parasitemia  
(No of parasite /µl of blood) 
 
Microscopy  
( No of positive) 
 
CareStart™  
(No of positive) 
 
Sensitivity (%) 
               201 198           98.5
a
 
      >5,000 ND ND           ND 
      1001 - 5,000 32 32           100 
      501 - 1,000 108 108           100 
      100 – 500 53 53            100 
      < 100 8 5            62.5 
ND -   No data, a- over all sensitivity 
 
Discussion 
In this study, the performance of the CareStartTM was 
found to be highly sensitive for the detection of both P. 
falciparum and P. vivax infections as previously reported 
from other parts of Ethiopia (15, 16), Uganda (20) and 
Madagascar (10). Recent studies have shown that its 
sensitivity is low when the parasite density is less than 
100 parasites/μl of blood (16, 21). In this study, three 
false-negative results were found for P. falciparum 
infection in individuals having parasite density less than 
100 parasites/μl of blood. In addition to the low parasite 
density, factors like poor flow characteristics, 
monoclonal antibody failure (8, 22) and variation in the 
number of epitopes present in a particular parasite isolate 
could also be responsible for the false negative results. 
 
The specificities of CareStart
TM
 observed here for the 
diagnosis of P. falciparum (98.0%) and P. vivax (99.6%) 
infections are comparable with previous findings by 
Sheraw et al. (15) and Mekonene et al.(16), but higher 
than the specificities reported by Ratsimbasoa et al. (10) 
and Fogg et al. (20). False positivity could be due to the 
persistence of HRP2 antigen in patients who had been 
treated in the preceding 30 days in case of P. falciparum 
(9). Furthermore, occasional false-positive results 
because of rheumatoid factors have previously been 
reported with diagnostic devices based on the detection 
of HRP 2 (13, 23). On the other hand, sequestration may 
also reduce the number of circulating parasites to below 
the microscopic threshold detection level of 
approximately 50 parasites /µl of blood at the time of 
blood collection which might result in false negative 




 Malaria Pf/Pv Combo test (Lot No H28IV 
which was stored at the surrounding temperature of the 
Afar Region at Dubti Hospital for one year duration) and 
CareStart 
TM
 Malaria Pf/Pv Combo test (Lot No H 38IV) 
which was stored at Addis Ababa, revealed similar 
results (Table 3).  This also indicates that the high 
temperature of the study area might not have significant 
impact on the test performance of the Care Start. Hence, 
the test fulfills the performance criteria set for the rapid 





 Malaria Pf/Pv Combo test showed a 
comparable diagnostic performance with blood film 
microscopic examination results for the diagnosis of P.  
falciparum and P. vivax  infections. It has the added 
advantage of being simple to process, interpret, and quick 
to use as a diagnostic assay. Hence, it can be used in rural   
health service facilities where laboratory equipment, 
electricity, and skilled microscopists are scarce, as is the 
case in the Afar Region. Further studies may be needed 
to evaluate the performance of the test in the hottest areas 
of the Region. 
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